Anti-PD-L1 antibody and use thereof
US11407834B2 · kind B2 · utility
0Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 27, 2018 |
| Grant date | Aug 9, 2022 |
| Priority date | — |
| Expiry date | Apr 16, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, a pharmaceutical composition for preventing or treating cancer containing the same, and a composition for co-administration with an antibody other than an antibody binding to PD-L1, containing the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.